Recipharm invests in its Italian API facility

Recipharm, the contract development and manufacturing organisation (CDMO), has announced an investment of over €1.2 million to enhance its small scale GMP active pharmaceutical ingredient (API) development and manufacturing capabilities in Paderno Dugnano, Italy. 

The investment, which is in response to growing demand for Recipharm’s custom synthesis and early phase API manufacturing capabilities, has seen the opening of a new GMP kilo laboratory. The new area enhances the output of the facility’s existing laboratories and offers a fully GMP compliant service.

Commenting on the investment, Matteo Zacché, R&D Manager at Recipharm in Paderno Dugnano, said: “This project is of strategic importance to Recipharm, enhancing our ability to offer drug developers a complete service offering from raw material to finished drug product”.

“With the addition of the new laboratory, we are now able to run up to six customer projects in parallel, handling maximum batch sizes of approximately 5 kg, compared to 1 kg previously. As well as increasing our output, we will also be investing in a number of new technologies, including flow chemistry, chromatography and hydrogenation capabilities in line with growing customer demand.”

As part of the investment, the facility’s existing chemical development laboratories have been upgraded, with the addition of new technologies and a dedicated unit for analytical development and method analysis activities. Analytical technologies under evaluation include high performance liquid chromatography-mass spectrometry (HPLC-MS), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR) spectroscopy and ultra-performance liquid chromatography (UPLC) method scouting solutions.

To support the new capabilities, Recipharm plans to double its R&D team in Paderno Dugnano over the next three years.

Recipharm’s team in Paderno Dugnano specialise in the GMP scale-up and manufacture of APIs for all clinical phases, from gram to kilo and pilot scale to commercial supply. The facility has advanced technical transfer capabilities and expertise in the development of chemical processes and analytical methods up to registration on a global basis. 

Contact information
Matteo Zacché, R&D Manager, matteo.zacche@recipharm.com , +39 02910011347
Carl-Johan Spak, Executive Vice President Global Technologies, carl-johan.spak@recipharm.com , + 46 8 602 53 13

For media enquiries, please contact Lindsay Baldry at ramarketing: lindsay@ramarketingpr.com + 44 ( 0)191 222 1242 , ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr,  Linkedin: /ramarketing

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) (in the pharmaceutical industry employing around 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and its services, please visit www.recipharm.com

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden,  Telephone 46 8 602 52 00,  Fax  46 8 81 87 03

www.recipharm.com

Tags:

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links

Quotes

This project is of strategic importance to Recipharm, enhancing our ability to offer drug developers a complete service offering from raw material to finished drug product. With the addition of the new laboratory, we are now able to run up to six customer projects in parallel, handling maximum batch sizes of approximately 5 kg, compared to 1 kg previously. As well as increasing our output, we will also be investing in a number of new technologies, including flow chemistry, chromatography and hydrogenation capabilities in line with growing customer demand.
Matteo Zacché, R&D Manager at Recipharm in Paderno Dugnano